AAIC 2026 evidence shows a combined amyloid-beta and phosphorylated-tau blood test reached about 90% diagnostic accuracy in real clinics. For people with mild cognitive impairment, it offers lower-cost triage with clear next steps before treatment.
Mild cognitive impairment means noticeable memory or thinking changes that do not block daily tasks. According to the Alzheimer's Association press release reported in the AAIC 2026 study summary, the test changed diagnosis in one-third of 1,300-plus patients and changed care plans in over half. The Alzheimer's Association's 2025 guideline limits such testing to people with mild cognitive impairment or dementia seen in specialty care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How well do blood tests work in real clinics?
- Which tests can you get now?
- How much will you pay?
- What should you ask after an MCI result?
How well do blood tests work in real clinics?
The AAIC 2026 real-world study followed more than 1,300 patients and 165 physicians. Both primary-care doctors and specialists reached about 90% accuracy when they added the amyloid-beta plus phosphorylated-tau test to clinical evaluation. That gain mattered for planning.
A new test result led doctors to revise the diagnosis for one in three patients. It also led to a new care plan for more than half, such as referrals, counseling, safety planning, or further testing. The result does not replace clinical judgment. Blood markers measure Alzheimer's proteins, while memory, function, medicines, mood, and other brain conditions still shape the final diagnosis.
Which tests can you get now?
The U.S. Food and Drug Administration cleared Fujirebio's Lumipulse blood test on May 16, 2025 for adults age 55 and older with signs of cognitive decline. It measures the pTau217 to beta-amyloid 1-42 ratio in plasma as an aid to detect amyloid plaques. It is not a standalone diagnosis and is not for screening without symptoms. As of August 24, 2026, four tests were FDA-cleared, according to the Cure Alzheimer's Fund test tracker.
They are C2N PrecivityAD2, Lumipulse pTau217/beta-Amyloid 1-42 ratio, Roche Elecsys pTau181, and Roche Elecsys pTau217. More than 10 other tests remain for sale without FDA clearance, with varied accuracy. The Alzheimer's Association guideline sets high bars for use. Triage tests should reach at least 90% sensitivity and 75% specificity. Confirmatory tests should reach at least 90% for both compared with PET, spinal-fluid testing, or brain pathology.
How much will you pay?
Blood tests cost far less than amyloid PET or lumbar puncture, but prices vary widely. According to Being Patient's August 2026 price review, Labcorp lists pTau217 at $277 and its ATN panel at $626. The same review lists Quest AD-Detect at $399 and C2N PrecivityAD2 at $1,450. Insurance payment remains limited.
The review reports Medicare reimbursement of about $130 for cleared tests. Ask the clinic for the exact test name, FDA-clearance status, billing code, and prior-authorization rules before blood is drawn. Access is uneven because many clinics still send samples to central labs. Specialty memory clinics are more likely to offer cleared tests and explain confirmatory options than general practices with no dementia pathway.
What should you ask after an MCI result?
A positive blood test in mild cognitive impairment starts a plan, not a final answer. Guidelines advise confirmatory amyloid PET or spinal-fluid testing plus clinical evaluation because blood tests alone cannot give a definitive Alzheimer's diagnosis.
False positives remain high in younger or cognitively healthy people. Bring these questions to the follow-up visit: Medicare drug coverage requires confirmed amyloid and registry enrollment, according to the 2023 PET coverage change and 2026 coverage summary. A written plan should name the confirmatory test, treatment eligibility, side-effect watches, and the date for recheck of thinking and daily function.
- Was this an FDA-cleared test, and what were my exact values?
- Do I need confirmatory amyloid PET or spinal-fluid testing?
- Do my medicines, vascular risk, sleep apnea, depression, or other causes explain my symptoms?
- If anti-amyloid treatment is possible, what brain scans, safety checks, and registry steps does Medicare require?
- What monitoring, driving, work, counseling, and caregiver-support plan fits my stage?
You Might Also Like
- The AAIC 2026 Swedish Real-World Blood Test Study: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
